Alliance Announces FDA Acceptance of Supplemental Biologics License Application Supported by Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by…